Invivyd (IVVD) Surged 7.21% as SPEAR Study Group Recommends VYD2311 Long COVID Antibody Study Design

Invivyd (IVVD) surged 7.2072% in pre-market trading on December 17, 2025, as investors reacted to recent developments in its therapeutic pipeline and strategic collaborations.

The rally followed the company’s announcement that the SPEAR Study Group has recommended a study design for its Long COVID antibody candidate, VYD2311. This initiative, set to be presented at the RECOVER-TLC Workshop, underscores Invivyd’s focus on advancing monoclonal antibody therapies for post-viral conditions. Analysts noted that alignment with regulatory pathways for rapid approval of VYD2311 could position the firm as a key player in the evolving post-pandemic healthcare landscape.

Recent financing activities also drew attention, with Invivyd completing a $57.5 million public offering in August 2025. While some analysts trimmed their price targets for the stock, HC Wainwright reaffirmed a “Buy” rating in late August, citing the company’s potential in long-term therapeutic innovation. Insider selling activity in the preceding weeks, however, highlighted mixed sentiment among stakeholders.

The stock’s pre-market jump reflects optimism around its pipeline advancements, despite ongoing challenges in the competitive monoclonal antibody space. Investors will likely monitor upcoming clinical data and regulatory updates to gauge the sustainability of the momentum.

As the sector continues to evolve, key developments in regulatory approvals and clinical trial outcomes will remain central to investor sentiment. Market analysts remain cautiously optimistic but emphasize the importance of near-term data releases and strategic partnerships in determining the company's trajectory.